Statistical considerations when using a composite endpoint for comparing treatment groups

Stat Med. 2013 Feb 28;32(5):719-38. doi: 10.1002/sim.5547. Epub 2012 Aug 1.

Abstract

When comparing two treatment groups in a time-to-event analysis, it is common to use a composite event consisting of two or more distinct outcomes. The goal of this paper is to develop a statistical methodology to derive efficiency guidelines for deciding whether to expand a study primary endpoint from E1 (for example, non-fatal myocardial infarction and cardiovascular death) to the composite of E1 and E2 (for example, non-fatal myocardial infarction, cardiovascular death or revascularisation). We investigate this problem by considering the asymptotic relative efficiency of a log-rank test for comparing treatment groups with respect to a primary relevant endpoint E1 versus the composite primary endpoint, say E, of E1 and E2, where E2 is some additional endpoint.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • AIDS Vaccines / administration & dosage
  • Acute Coronary Syndrome / complications
  • Acute Coronary Syndrome / drug therapy
  • Acute Coronary Syndrome / mortality
  • Anti-HIV Agents / administration & dosage
  • Anticholesteremic Agents / therapeutic use
  • Biostatistics / methods*
  • Endpoint Determination / statistics & numerical data*
  • HIV Infections / drug therapy
  • HIV Infections / immunology
  • Humans
  • Probucol / analogs & derivatives
  • Probucol / therapeutic use
  • Randomized Controlled Trials as Topic / statistics & numerical data*

Substances

  • AIDS Vaccines
  • Anti-HIV Agents
  • Anticholesteremic Agents
  • HIV-1 immunogen, incomplete Freund's adjuvant
  • succinobucol
  • Probucol